CARGO Therapeutics, Inc. (CRGX)
NASDAQ: CRGX · Real-Time Price · USD
14.90
+1.39 (10.29%)
At close: Dec 20, 2024, 4:00 PM
14.77
-0.13 (-0.87%)
After-hours: Dec 20, 2024, 4:23 PM EST
Company Description
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients.
The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets.
The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022.
CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
CARGO Therapeutics, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Nov 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Gina Chapman |
Contact Details
Address: 1900 Alameda De Las Pulgas, Suite 350 San Mateo, California 94403 United States | |
| Phone | 650 379 6143 |
| Website | cargo-tx.com |
Stock Details
| Ticker Symbol | CRGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001966494 |
| CUSIP Number | 14179K101 |
| ISIN Number | US14179K1016 |
| Employer ID | 84-4080422 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gina Chapman | President, Chief Executive Officer and Director |
| Dr. Crystal L. Mackall M.D. | Co-Founder and Scientific Advisory Board Chair |
| Anup Radhakrishnan | Chief Financial Officer, Secretary and Chief Operating Officer |
| Dr. Ginna G. Laport M.D. | Chief Medical Officer |
| Dr. Robbie Majzner M.D. | Co-Founder and Scientific Advisory Board Member |
| Nancy Goodman J.D. | Founder |
| Dr. Louai Labanieh | Founder |
| Faisal Shawwa M.B.A. | Senior Vice President of Finance and Accounting |
| Dr. Shishir Gadam Ph.D. | Chief Technical Officer |
| Dr. Michael Ports Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 6, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |